Concurrent minimal change nephrotic syndrome and type 1 diabetes mellitus in an adult Japanese woman: a case report

Ryuzoh Nishizono 1, Hiroki Kogou 1, Yuri Ishizaki 1, Akihiro Minakawa 1, Masao Kikuchi 1, Hiroko Inagaki 2, Yuji Sato 1,2 and Shouichi Fujimoto 2,3

Abstract

Background: Concurrent type 1 diabetes mellitus (T1DM) and idiopathic nephrotic syndrome is rare, and most previously reported cases were in children. We report the case of an adult woman who developed T1DM and minimal change nephrotic syndrome (MCNS) nearly simultaneously.

Case presentation: A 24-year-old woman had first presented to another hospital with nausea, vomiting, and fatigue. She was diagnosed with diabetic ketoacidosis and T1DM on the basis of her hyperglycemia, ketoacidosis, and positive anti-glutamic acid decarboxylase antibody test result. Rapid infusion of normal saline and insulin administration alleviated hyperglycemia and ketoacidosis. Two weeks after admission, however, she developed nephrotic syndrome (NS) with rapidly decreasing urine volume. She was referred to our hospital with a diagnosis of acute kidney injury. Although she temporarily required dialysis and high doses of insulin, within 1 month NS and acute kidney injury had been alleviated by oral prednisolone and low-density lipoprotein apheresis. Renal biopsy showed minor glomerular abnormalities without diabetic nephropathy, so we diagnosed her with MCNS. Seven weeks after the discharge, NS relapsed, and cyclosporine was added to prednisolone. However, NS relapsed twice within the next 4 months, so we started her on rituximab. At 6 months after initiating rituximab therapy, she remained in complete remission.

Her mother also had T1DM but not MCNS. The patient had HLA-DRB1*09:01/09:01, DQB1*03:03/03:03, and her mother had HLA-DRB1*04:05/09:01, DQB1*03:03/04:01.

Conclusions: Concurrent T1DM and MCNS is rare and their coexistence might be coincidental. Alternatively, they might have been caused by an underlying, unidentified genetic predisposition. Previous reports and our patient’s findings suggest that specific HLA alleles and haplotypes or a Th1/Th2 imbalance might be associated with T1DM and MCNS that occurred nearly simultaneously.

Keywords: Type 1 diabetes mellitus, Steroid-sensitive nephrotic syndrome, Minimal change nephrotic syndrome, Genetic factors

© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Type 1 diabetes mellitus (T1DM) and idiopathic nephrotic syndrome are more common in children than in adults. The incidence of T1DM in Japanese children < 14 years of age is 1.4–2.25/100,000 [1], which is much lower than that in other countries, especially Finland (45.0–64.2/100,000 children < 15 years of age) [2]. Conversely, the estimated incidence of pediatric idiopathic nephrotic syndrome in Japan is 6.49 cases/100,000 [3], which is slightly higher than the average incidence in previous studies worldwide (4.7/100,000) [4]. Most cases of pediatric idiopathic nephrotic syndrome manifest as minimal change nephrotic syndrome (MCNS) in Japan, which is similar to that in other countries.

Some case reports described children who had developed idiopathic nephrotic syndrome soon after being diagnosed with T1DM, whereas others, conversely, had developed T1DM soon after being diagnosed with idiopathic nephrotic syndrome [5–11]. Most patients with MCNS had neither diabetic nephropathy nor retinopathy. We report a rare case in which an adult woman developed T1DM and MCNS nearly simultaneously. We then discuss the patient’s genetic background.

Case presentation
A 24-year-old Japanese woman was admitted to another hospital with nausea, vomiting, and general fatigue. She had a 2-month history of strongly feeling thirsty, and she had lost 5 kg during that period. She had no history of infectious diseases such as bronchitis before feeling thirsty. Her only medical history was seasonal allergic rhinitis, but her family history included T1DM. Her mother was diagnosed with T1DM at 29 years of age. She was referred to our hospital with nausea, vomiting, and general fatigue.

On admission, she was found to have gained 4 kg in weight within the past 2 weeks due to oliguria. Physical examination showed lower-leg pitting edema. Her blood pressure was 106/66 mmHg, and urinalysis and blood test results revealed findings that were consistent with nephrotic syndrome and renal dysfunction (Table 1).

| Blood test                      | 4.83  |
|---------------------------------|-------|
| Serum albumin (g/dL)            | 1.28  |
| Blood urea nitrogen (mg/dL)     | 54.0  |
| Serum creatinine (mg/dL)        | 4.04  |
| Total cholesterol (mg/dL)       | 434   |
| Plasma glucose (mg/dL)          | 85    |
| Hemoglobin A1c (%)              | 12.7  |
| Serum C-peptide (ng/mL)         | 2.0 (1.2–2.0) |
| Serum IgG (mg/dL)               | 479 (861–1747) |
| Serum IgE (IU/mL)               | 4882 (3.7–311.6) |
| Free triiodothyronine (FT3) (pg/mL) | 1.5 (1.88–3.18) |
| Free thyroxine (FT4) (ng/dL)    | 0.78 (0.7–1.48) |
| Thyroid stimulating hormone (µIU/L) | 1.01 (0.35–4.94) |

Table 1: Patient’s laboratory data at admission

Her serum immunoglobulin E (IgE) level was very high (4882 IU/mL), and there was no eosinophilia.

Insulin treatment for T1DM was continued, and hemodialysis was initiated on day 2 and continued three times per week because of acute kidney injury. A renal biopsy was performed on day 15 after admission. Among the 46 glomeruli that were obtained in the biopsy, one glomerulus showed global sclerosis, and the others showed some mesangial matrix expansion but without hypercellularity or extracapillary or endocapillary proliferation. The pathological diagnosis was minor glomerulosclerosis (FSGS), we started low-

...
density lipoprotein apheresis (LDL-A) on day 42. LDL-A was performed twice a week for 3 weeks. Her urinary protein decreased, and the urine volume gradually increased. On day 55, she was in complete remission. PSL was tapered by 10 mg every 2 weeks, and she was discharged from the hospital at a reduced PSL dose of 30 mg/day on day 71.

Seven weeks later, the patient had a relapse of nephrotic syndrome, and cyclosporine 1.5 mg/kg (75 mg/day) was added to PSL. However, NS relapsed twice within the next 4 months, so we started her on a single dose of rituximab (375 mg/m²) after explaining the prognosis of frequently relapsing nephrotic syndrome. Serum CD19/CD20 levels decreased to 0.1/0.0% after 1 month, and we discontinued cyclosporine. PSL was tapered from 30 mg/day to 5 mg/day over 6 months, and hemoglobin A1c remained at 7.1–7.9% with insulin treatment. At 6 months after initiating rituximab, she remained in complete remission without any reported side effects.

Fig. 1 Micrographs of renal biopsy findings. a Light micrograph of a glomerulus shows no evidence of diabetic nephropathy (periodic acid-Schiff stain). b Glomerulus shows positive immunofluorescence staining for immunoglobulin G (IgG) along a capillary wall. c Electron micrograph shows effacement of the podocyte foot process and a glomerular capillary membrane of normal thickness without evidence of capillary immune complex deposits. (A × 400; B × 400; C × 5000)

Fig. 2 Clinical course. *PMT, pulse methylprednisolone therapy: 500 mg of methylprednisolone intravenously for 3 days.
To investigate the genetic background of the co-occurrence of both diseases, we performed an HLA testing on the patient and her mother. The patient had HLA-DRB1*09:01/09:01, DQB1*03:03/03:03, and her mother had HLA-DRB1*04:05/09:01, DQB1*03:03/04:01.

Discussion and conclusions
We report the rare case of a young woman who developed T1DM and MCNS nearly simultaneously. We later found that her mother also had T1DM. The patient had no diabetic retinopathy or nephropathy, but her hemoglobin A1c was 12.7%. A previous report noted that the glomerular basement membrane was partially thickened in a patient 6 months after being diagnosed with diabetes mellitus [12, 13], but it was not thickened in our patient. A possible explanation is that she had developed subclinical acute-onset T1DM a few months before admission, which had manifested as a strong feeling of thirst during the 2 months before her admission. She had also lost weight (5 kg).

Although renal biopsy showed minor glomerular abnormalities, it might have been FSGS because she required LDL-A as the initial treatment and her nephrotic syndrome relapsed several times. She had no diabetic nephropathy, but a trace of linear IgG deposition in the capillary walls was revealed by immunofluorescence staining. We could not determine whether the deposition was an immunological reaction or a non-specific change that is occasionally seen in MCNS/FSGS patients.

Table 2 Summary of previous reports of patients with nephrotic syndrome with type 1 diabetes mellitus that developed within 1 year

| References       | Age at onset of T1DM (years) | Age at onset of NS (years) | Pathological diagnosis         | Treatment         | Outcome                  |
|------------------|------------------------------|---------------------------|--------------------------------|-------------------|--------------------------|
| Robinson [12]    | 8                            | 8                         | Not done                       | Steroid, Diuretics| Resolved completely     |
| Urizar [11]      | 4                            | 4 (1 week after DM)       | Normal                         | Insulin           | Resolved completely     |
|                  | 3.3                          | 4.3                       | Minimal focal glomerulitis     | Steroid           | Resolved completely     |
|                  | 5                            | 5                         | Minimal focal glomerulitis     | Steroid           | Recurrence              |
| Robbinson [10]   | 3                            | 3 (2 months after DM)     | ICGN                           | Steroid           | Resolved completely     |
| Dornan [9]       | 20                           | 20 (2 weeks after DM)     | MCD                            | Diuretics         | Resolved                |
|                  | 13                           | 13 (1 week after DM)      | Not done                       | Steroid, CPM      | Resolved spontaneously  |
| Rego Filho [7]   | 3.9                          | 3.9                       | Not done                       | Steroid, CPM      | Resolved                |
| Nakahara [23]    | 8                            | 8                         | MCD                            | Steroid, CPM      | ?                        |
| Agras [24]       | 3                            | 3 (10 months after DM)    | Not done                       | Steroid, CPM      | Resolved                |
| Jameela [25]     | 2.75                         | 2.75                      | Diffuse expansion of mesangial matrix | Steroid, CPM | Resolved                |
|                  | 1.5                          | 1.5                       | Diffuse expansion of mesangial matrix | Steroid, CPM | Resolved                |
| Otukesh [6]      | 13 days                      | 13 days                   | MGN                            | ?                 | ?                        |

T1DM Type 1 diabetes mellitus, NS Nephrotic syndrome, CPM Cyclophosphamide, MGN Membranous glomerulonephritis, MCD Minimal-change disease, ICGN Immune-complex glomerulonephritis
alleles are associated with susceptibility to T1DM. Additionally, HLA-DRB1*04:05-DQB1*04:01, HLA-DRB1*08:02-DQB1*03:02, and HLA-DRB1*09:01-DQB1*03:03 haplotypes are associated with susceptibility to T1DM [29]. Recently, it has been reported that the HLA-DRB1*08:02, HLA-DQB1*03:02 alleles, and the HLA-DRB1*08:02-DQB1*03:02 haplotype is highly associated with steroid-sensitive nephrotic syndrome in Japanese children [30]. Although we had speculated that our patient would have HLA-DRB1*08:02-DQB1*03:02, she had HLA-DRB1*09:01/09:01 and DQB1*03:03/03:03. Her mother had HLA-DRB1*04:05/09:01 and DQB1*04:01/03:03. Both the patient and her mother had specific HLA haplotypes that are highly associated with T1DM, but only the daughter developed MCNS. HLA-DRB1*09:01-DQB1*03:03-DPB1*02:01 and HLA-A*02:06-C*08:01-B*40:06-DRB1*09:01-DQB1*03:03 haplotypes have been reported to be associated with childhood steroid-sensitive nephrotic syndrome in Japan, so our patient might have either one of the two haplotypes [30].

Another hypothesis that explains concurrent T1DM and MCNS is Th1/Th2 imbalance [31–35]. Both diseases have a strong association with T-cell abnormalities, although the mechanisms are different. MCNS is known to be associated with allergic disease [36], and it has been reported to be associated with prevalent type 2 helper T-cell (Th2) responses. The association of T1DM with autoimmune disorders is also well known [37], and its association with prevalent type 1 helper T-cell (Th1) responses has been reported. However, neither Th1 predominance in T1DM nor Th2 predominance in MCNS has not been definitively identified [38, 39].

Previous case reports described that insulin treatment influenced T-cell differentiation and promoted a shift toward a Th2-type response [40–42]. These previous reports strongly suggested that insulin could function as a glucose-regulatory hormone and as a T-cell hormone, which enhances the Th2 response and consequently increases the in vitro production of Th2 profile cytokines such as interleukin (IL)-4 and IL-10 in patients who are at high risk of DM and T1DM.

In the present case, the patient developed T1DM first, followed by MCNS 2 weeks later. We speculate that these diseases were manifest via two different mechanisms. First, insulin lispro (or aspart) administration might cause a drastic shift in the Th1 response to a Th2 response. Second, insulin lispro may have triggered an allergic reaction causing MCNS because she developed an itchy eruption shortly after the first insulin lispro injection and had a high level of serum IgE. No previous reports, however, have demonstrated the simultaneous onset of T1DM and MCNS, and due to a Th1/Th2 imbalance, and we did not measure the Th1/Th2 ratios and serum cytokine levels that were secreted by Th1 and Th2.

In summary, we report the rare case of an adult woman with acute kidney injury that resulted from MCNS, which had developed soon after she was diagnosed with diabetic ketoacidosis that was caused by T1DM. The mechanism by which T1DM and MCNS occurred concurrently remains unclear, although some previous reports and our case indicate that genetic factors (e.g., specific HLA alleles and haplotypes) or a Th1/Th2 imbalance might be associated with the onset of these two diseases.

### Supplementary information

**Supplementary information**

Supplementary information accompanies this paper at https://doi.org/10.1186/s12882-020-02071-6.

### Additional file 1.

**Abbreviations**

T1DM: Type 1 diabetes mellitus; NS: Nephrotic syndrome; MCNS: Minimal change nephrotic syndrome; IgG: Immunoglobulin G; GAD: Glutamic acid decarboxylase; IA-2: Insulinoma-associated antigen-2; ZnT8: Zinc transporter 8; CPM: Cyclophosphamide; LDL-A: Low-density lipoprotein apheresis; MGN: Membranous glomerulonephritis; CPM: Cyclophosphamide; LDL-A: Low-density lipoprotein apheresis; FSGS: Focal segmental glomerulosclerosis; ICGN: Immune-complex glomerulonephritis; HLA: Human leukocyte antigen

**Acknowledgments**

We thank Nancy Schatken, BS, MT (ASCP), from Edanz Group (https://en-author-services.edanzgroup.com/ac), for editing a draft of this manuscript.

**Authors’ contributions**

RN and SF planned and wrote the case report. RN, HK, YI, MK, and HI clinically cared for the patient and participated in clinical data acquisition. MK, YS, and YI performed the renal biopsy. AM pathologically diagnosed the patient and revised the manuscript. RN, MK, YS, and SF analyzed the patient’s clinical course and interpreted the data. RN wrote a draft of the manuscript, and YS and SF revised it critically. All authors read and approved the final manuscript.

**Funding**

Not applicable.

**Availability of data and materials**

All data supporting the case are included in the manuscript.

**Ethics approval and consent to participate**

Not applicable.

| Case          | HLA class II                                                                 |
|---------------|------------------------------------------------------------------------------|
| Rego Filho    | DR 4, DR 8, DR 53                                                          |
| Peces         | DR 4, DR 7                                                                  |
| Kagiyama      | DR 2, DR 9                                                                  |
| Agras         | DR 4, DR 11, DR 52, DR 53, DQ 7, DQ 8                                       |
| Present case  | DR 9 (DRB1*09:01), DQ 9 (DQB1*03:03)                                        |

*HLA Human leukocyte antigen*
Consent for publication
Written informed consent was obtained from the patient for publication of this case report and accompanying images.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Nephrology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan. 2Division of Nephrology, University of Miyazaki Hospital, Miyazaki, Japan. 3Department of Hemovascular Medicine and Artificial Organs, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.

Received: 19 April 2020 Accepted: 15 September 2020
Published online: 23 September 2020

References
1. Onda Y, Sugihara S, Ogata T, Yokota S, Yokoyama T, Tajima N. Type 1 diabetes (T1D) study group. Incidence and prevalence of childhood-onset type 1 diabetes in Japan: the T1D study. Diabet Med. 2017;34(7):909–15.
2. Songini M, Mannu C, Taghertia C, Bruno G. Type 1 diabetes in Sarдинia: facts and hypotheses in the context of worldwide epidemiological data. Acta Diabetol. 2017;54(1):19–7.
3. Kikunaga K, Ishikura K, Terano C, Sato M, Komaki F, Hamasaki Y, et al. Japanese pediatric study holding information of NEphritic study group of the Japanese study Group of Renal Disease in children (JP-SHINE study). High incidence of idiopathic nephritic syndrome in East Asian children: a nationwide survey in Japan. Clin Exp Nephrol. 2017;21(4):651–7.
4. Chanchilani R, Parekh RS. Ethnic differences in children nephritic syndrome. Front Pediatr. 2016;4:39.
5. Bawabah NS, Safdar OY, Nagadi SA, Saeedi AT, Mohammed Hussain RW. ACE inhibitors to prevent and treat renal failure in Egyptian patients with type 1 diabetes: a randomized controlled trial. Diabetes Res Clin Pract. 2017;134:37–42.
6. Goland R, et al. Rituximab, B-lymphocyte depletion, and preservation of β-cell function in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet. 2011;378:412–9.
7. Pescovitz MD, Greenbaum CJ, Bundy B, Becker DJ, Gitelman SE, Goland R, et al. B-lymphocyte depletion with rituximab and β-cell function: two-year results. Diabetes Care. 2014;37(2):453–9.
8. Solomon LK, Gitelman S, Greenbaum C, et al. Immune tolerance network (ITN007/AI) study group treatment of patients with new onset type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin Immunol. 2009;132:166–73.
9. Keymeulen B, Walter M, Mathieu C, et al. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depending on their age and baseline residual β-cell mass. Diabetologia. 2010;53:614–23.
10. Orban T, Bundy B, Becker DJ, et al. Type 1 diabetes TrialNet Abatacept study group co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet. 2011;378:412–9.
11. Pescovitz MD, Greenbaum CJ, Bundy B, Becker DJ, Gitelman SE, Goland R, et al. B-lymphocyte depletion with rituximab and β-cell function: two-year results. Diabetes Care. 2014;37(2):453–9.
12. Solomons LG, Quigley S, Greenbank C, et al. London 007/AI study group treatment of patients with new onset type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin Immunol. 2009;132:166–73.
13. Keymeulen B, Walter M, Mathieu C, et al. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depending on their age and baseline residual β-cell mass. Diabetologia. 2010;53:614–23.
14. Orban T, Bundy B, Becker DJ, et al. Type 1 diabetes TrialNet Abatacept study group co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet. 2011;378:412–9.
15. Pescovitz MD, Greenbaum CJ, Bundy B, Becker DJ, Gitelman SE, Goland R, et al. B-lymphocyte depletion with rituximab and β-cell function: two-year results. Diabetes Care. 2014;37(2):453–9.
16. Solomons LG, Quigley S, Greenbank C, et al. London 007/AI study group treatment of patients with new onset type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin Immunol. 2009;132:166–73.
17. Keymeulen B, Walter M, Mathieu C, et al. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depending on their age and baseline residual β-cell mass. Diabetologia. 2010;53:614–23.
18. Orban T, Bundy B, Becker DJ, et al. Type 1 diabetes TrialNet Abatacept study group co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet. 2011;378:412–9.
19. Pescovitz MD, Greenbaum CJ, Bundy B, Becker DJ, Gitelman SE, Goland R, et al. B-lymphocyte depletion with rituximab and β-cell function: two-year results. Diabetes Care. 2014;37(2):453–9.
20. Solomons LG, Quigley S, Greenbank C, et al. London 007/AI study group treatment of patients with new onset type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin Immunol. 2009;132:166–73.
21. Keymeulen B, Walter M, Mathieu C, et al. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depending on their age and baseline residual β-cell mass. Diabetologia. 2010;53:614–23.
22. Orban T, Bundy B, Becker DJ, et al. Type 1 diabetes TrialNet Abatacept study group co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet. 2011;378:412–9.
23. Pescovitz MD, Greenbaum CJ, Bundy B, Becker DJ, Gitelman SE, Goland R, et al. B-lymphocyte depletion with rituximab and β-cell function: two-year results. Diabetes Care. 2014;37(2):453–9.
24. Solomons LG, Quigley S, Greenbank C, et al. London 007/AI study group treatment of patients with new onset type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin Immunol. 2009;132:166–73.
25. Keymeulen B, Walter M, Mathieu C, et al. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depending on their age and baseline residual β-cell mass. Diabetologia. 2010;53:614–23.
42. Kretowski A, Myśliwiec J, Szelachowska M, Kinalski M, Kinańka I. Insulin increases in vitro production of Th2 profile cytokines in peripheral blood cultures in subjects at high risk of diabetes type 1 and patients with newly diagnosed IDDM. Horm Metab Res. 1999;31(4):289–92.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.